n.a. (BPAX)

55.05
0.69 1.24
NASDAQ
Prev Close 55.74
Open 56.64
Day Low/High 54.22 / 56.64
52 Wk Low/High 12.79 / 56.99
Volume 182.41K
Exchange NASDAQ
P/E Ratio N/A
Div & Yield N.A. (N.A)

BioSante Pharmaceuticals Receives Two New Patents For Manufacture Of Proteins, Including Antibodies

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the receipt of two US new patents directed to its 2A/Furin technology for expressing proteins.

BioSante Pharmaceuticals Reports Recent Developments And First Quarter Financial Results

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today reported on its recent developments and financial results for the first quarter, and its cash balance as of March 31, 2010.

BioSante Pharmaceuticals, Inc. To Present At The Rodman & Renshaw Annual Global Investment Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Rodman & Renshaw Annual Global Investment Conference which will be held from May 16-18 in London, UK.

New Cancer Vaccine the Next Dendreon?

Cancer vaccines have a high failure rate, so investors looking for the next Dendreon take note.

BioSante Pharmaceuticals Announces Reinitiation Of Prostate Cancer Vaccine Development

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated.

BioSante Pharmaceuticals, Inc. To Present Cancer Vaccine Portfolio Update At The BIO International Convention

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present a BioSante cancer vaccine portfolio update at the BIO International Convention, which will take place May 3-6 in Chicago, Illinois.

BioSante Pharmaceuticals, Inc. To Present At The Deutsche Bank Healthcare Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the 35 th Annual Deutsche Bank Healthcare Conference to be held in the InterContinental Hotel, Boston from May 3-5, 2010.

BioSante Pharmaceuticals Enters Option Agreement To Its 2A/Furin Antibody Expression Technology

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it has entered into an Option Agreement with an undisclosed large multi-national pharmaceutical company to obtain a non-exclusive worldwide license for...

BioSante Pharmaceuticals, Inc. To Present And Participate In Cancer Immunotherapy Panel At The World Vaccine Congress

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present and separately participate in a cancer immunotherapy panel discussion at the World Vaccine Congress, which will take place April 19-22 in Washington, D.

BioSante Pharmaceuticals, Inc. Discusses LibiGel® And Its Cancer Vaccines In Fireside Chat With Research Analyst

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that a BioSante presentation and corporate discussion are available at http://www.

BioSante Pharmaceuticals Reports Receipt Of $2.16 Million In Elestrin™ Royalty Buydown, And Financial Results For 2009

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the successful completion of the Azur Pharma Elestrin royalty buydown, and financial results for the year ended December 31, 2009.

Sirius XM, Conolog: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Tuesday's session.

BioSante Announces Additional Positive Leukemia Vaccine Results And Second FDA Orphan Drug Designation

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced positive GVAX AML Vaccine results and BioSante’s receipt of Orphan Drug designation from the FDA’s Office of Orphan Products Development for ...

Rodman & Renshaw And BioSante Pharmaceuticals, Inc. Announce Fireside Chat On Women's Health

Rodman & Renshaw (NASDAQ: RODM) and BioSante (NASDAQ: BPAX) today announced that Rodman will host Stephen M.

BioSante Announces FDA Orphan Drug Designation For GVAX Pancreatic Cancer Vaccine

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced BioSante’s receipt of Orphan Drug designation from the FDA’s Office of Orphan Products Development for GVAX Pancreas Vaccine in the treatment of ...

BioSante Announces Positive Leukemia Vaccine Results

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in...

BioSante Pharmaceuticals Closes $18 Million In Registered Direct Offering

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the closing of the sale, directly to funds affiliated with two institutional investors, of an aggregate of approximately 10.

BioSante Pharmaceuticals Receives Two New Patents For Manufacture Of Proteins, Including Antibodies

BioSante Pharmaceuticals Receives Two New Patents For Manufacture Of Proteins, Including Antibodies

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the receipt of two US patents directed to its 2A/Furin technology for expressing proteins.

Biotech Stock Mailbag: BioSante Pharma

Biotech Stock Mailbag: BioSante Pharma

Biotech watchdog Adam Feuerstein addresses readers' questions about BioSante and other healthcare stocks.

BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data In Phase III Program

BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data In Phase III Program

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX), today announced additional positive safety data in its ongoing LibiGel Phase III clinical development program.

BioSante Pharmaceuticals, Inc. To Present LibiGel® Clinical Update At ISSWSH Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), will present a LibiGel clinical update at the 2010 Annual Meeting of the International Society for the Study of Women’s Sexual Health (ISSWSH), being held from ...

BioSante Pharmaceuticals Rated Among Top 15 Companies On The Biotechnology Patent Scorecard™ As Published In The Wall Street Journal

BioSante Pharmaceuticals Rated Among Top 15 Companies On The Biotechnology Patent Scorecard™ As Published In The Wall Street Journal

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), has been ranked 15 th on The Patent Board’s list of the top 67 biotechnology companies as determined by an assessment of the overall quality of each company’s ...

BioSante Pharmaceuticals Appoints Jeffrey W. Winkelman, Ph.D., J.D., Vice President, Oncology Programs

BioSante Pharmaceuticals Appoints Jeffrey W. Winkelman, Ph.D., J.D., Vice President, Oncology Programs

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the appointment of Jeffrey W.

BioSante Pharmaceuticals, Inc. To Present At BIO CEO & Investor Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will be presenting at the 2010 BIO CEO & Investor Conference.

Early Movers: Pump Up the Volume

Early Movers: Pump Up the Volume

Several small-cap stocks were poised to move on above-average volume during Tuesday's session.

Early Movers: Pump Up the Volume

Early Movers: Pump Up the Volume

Several small-cap stocks were poised to move on above-average volume during Thursday's session.

BioSante Completes Cell Genesys Buyout

BioSante Completes Cell Genesys Buyout

BioSante-Cell Genesys to focus on developing therapy to treat female sexual dysfunction

BioSante Alters Terms Of Cell Genesys Deal

BioSante Alters Terms Of Cell Genesys Deal

BioSante adjusts exchange ratio in Cell Genesys acquisition; cos. to vote on tie-up Sept. 30

Biotech Stock Mailbag: Geron, Oculus, BioSante

Biotech Stock Mailbag: Geron, Oculus, BioSante

Geron, Oculus, BioSante, Gilead Sciences and Sequenom are among readers' stocks of interest in this special edition mailbag.

Lowe's, CIT Group, Charles Schwab Are Big Movers

Lowe's, CIT Group, Charles Schwab Are Big Movers

Lowe's, CIT Group, Charles Schwab, Aetna, Bank of America are among big market movers Monday